Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Vitamin D3 Not Recommended as Psoriasis Treatment

J Dermatolog Treat; ePub 2017 Aug 29; Jarrett, et al

Vitamin D3 supplementation (100,000 IU per month) is not recommended as a treatment for mild psoriasis, according to a recent study. Participants with psoriasis in a large, randomized, controlled trial examining the effect of vitamin D3 supplementation in adults aged 50-84 years, participated in a psoriasis sub-study over 12 months. The primary outcome was the Psoriasis Area and Severity Index (PASI) and secondary outcomes were Physicians Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Psoriasis Disability Index (PDI). 23 subjects were allocated to vitamin D and 42 to placebo; mean (SD) baseline 25-hydroxyvitamin D was 65.7 (25.7) nmol/L. Researchers found:

  • There was no significant difference at baseline between the 2 groups.
  • There were no significant differences between the groups in all of the psoriasis outcome measures.
  • Mean scores at 12 months for the placebo vs vitamin D groups: PASI 2.2 [1.4, 3.0] vs 2.1 [1.0, 3.2]; PGA 1.4 [1.1, 1.7] vs 1.5 [1.1, 1.9]; PDI 2.1 [0.9, 3.2] vs 1.9 [0.4, 3.4]; and DLQI 2.5 [1.4, 3.6] vs 2.0 [0.5, 3.4].

Citation:

Jarrett P, Camargo Jr CA, Coomarasamy C, Scragg R. A randomized, double-blind, placebo-controlled trial of the effect of monthly vitamin D supplementation in mild psoriasis. [Published online ahead of print August 29, 2017]. J Dermatolog Treat. doi:10.1080/09546634.2017.1373735.

Commentary:

Although topical therapy with vitamin D analogues are indicated for the treatment of psoriasis, this study demonstrated that supplementation with Vitamin D3 did not exhibit significant improvement in PASI scores, PGA, and DLQI in patients with mild psoriasis. The limitation in this study was that enrolled patients had mild psoriasis and changes in lower PASI scores from baseline are not as sensitive compared to higher baseline PASI scores. Several decades ago, vitamin D3 supplementation was used to treat psoriasis. However extremely high doses were utilized and there were severe adverse events, such as tetany and hypercalcemia. —Paul S. Yamauchi, MD, PhD

This Week's Must Reads

Dermatologist-Delivered Intervention Is Effective, JAMA Dermatology; ePub 2018 Aug 8; Mallett, et al

HRQOL in Patients with Cutaneous T-Cell Lymphoma, Int J Dermatol; ePub 2018 Aug 3; Holahan, Farah, et al

Disparities Seen in Access to Injectable Biologics , J Dermatolog Treat; ePub 2018 Aug 4; Feng, et al

Psoriasis Not Associated with Higher Dementia Risk, J Am Acad Dermatol; ePub 2018 Aug 6; Pezzolo, et al

Discerning Merkel Cell Carcinoma from Other Tumors, Am J Dermapathol; ePub 2018 Jul 24; Bandino, et al

Must Reads in Psoriasis

Psoriasis Not Associated with Higher Dementia Risk, J Am Acad Dermatol; ePub 2018 Aug 6; Pezzolo, et al

Psoriasis, Nonalcoholic Fatty Liver Disease Linked, J Clin Asthet Dermatol; 2018 Jun 1; Awosika, et al

Dietary Recommendations for Adults with Psoriasis, JAMA Dermatology; ePub 2018 Jun 20; Ford, et al

20% of Patients with Psoriasis Found to Have PsA, J Am Acad Dermatol; ePub 2018 Jun 18; Alinaghi, et al

Citizen Pscientist: Important New Research Tool, Dermatol Ther (Heidelb); ePub 2018 Jun 6; Sanchez, et al